share_log

Benchmark Reiterates Speculative Buy on OncoCyte, Maintains $5 Price Target

Moomoo 24/7 ·  Apr 15 11:09

Benchmark analyst Bruce Jackson reiterates OncoCyte (NASDAQ:OCX) with a Speculative Buy and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment